Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Vijay Rajendran"'
Autor:
Hendrik Schulze-Koops, Tsutomu Takeuchi, Daniel Aletaha, Maya H Buch, Yoshiya Tanaka, Ricardo Blanco, Paul Emery, Jacques-Eric Gottenberg, Bernard G Combe, Roberto Caporali, Patrick Verschueren, Vijay Rajendran, Anna Zubrzycka-Sienkiewicz, Edmund V Ekoka Omoruyi, Francesco De Leonardis
Publikováno v:
RMD Open, Vol 10, Iss 4 (2024)
Background Janus kinase inhibitors are an effective option for achieving sustained remission or low disease activity in patients with rheumatoid arthritis (RA) following inadequate response to conventional synthetic disease-modifying anti-rheumatic d
Externí odkaz:
https://doaj.org/article/876c49e5e08a4163a919ba3850e5bc79
Autor:
Yoshiya Tanaka, Tsutomu Takeuchi, Tatsuya Atsumi, Bernard G. Combe, Daniel Aletaha, Toshihiko Kaise, Vijay Rajendran
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 6, Pp 1399-1415 (2023)
Abstract Filgotinib is an oral preferential Janus kinase 1 inhibitor that demonstrated significant reductions in radiographic progression, with an acceptable tolerability and safety profile, vs placebo in patients with rheumatoid arthritis (RA) and a
Externí odkaz:
https://doaj.org/article/9d82d21b56b644fa97f3e0c2369b2bb0
Autor:
Alejandro Balsa, Siegfried Wassenberg, Yoshiya Tanaka, Anne Tournadre, Hans-Dieter Orzechowski, Vijay Rajendran, Udo Lendl, Pieter-Jan Stiers, Chris Watson, Roberto Caporali, James Galloway, Patrick Verschueren
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 6, Pp 1555-1574 (2023)
Abstract Introduction This post hoc analysis of the phase 3 rheumatoid arthritis (RA) filgotinib clinical trial program assessed the effect of filgotinib on body mass index (BMI) in patients with RA and the impact of BMI on the efficacy and safety of
Externí odkaz:
https://doaj.org/article/cb7d913272d643b0add44635e413c404
Autor:
Yoshiya Tanaka, Tatsuya Atsumi, Daniel Aletaha, Beatrix Bartok, Alena Pechonkina, Ling Han, Kahaku Emoto, Shungo Kano, Vijay Rajendran, Tsutomu Takeuchi
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 1, Pp 161-185 (2022)
Abstract Introduction We conducted a post hoc analysis of efficacy and safety of filgotinib stratified by estimated radiographic progression rate before baseline (BL) in patients with rheumatoid arthritis (RA) who had inadequate response to methotrex
Externí odkaz:
https://doaj.org/article/5ad3c011326f47e39cc3a991b6b2f59f
Autor:
Jennie Ong, Wim Timens, Vijay Rajendran, Arjan Algra, Avrum Spira, Marc E Lenburg, Joshua D Campbell, Maarten van den Berge, Dirkje S Postma, Anke van den Berg, Joost Kluiver, Corry-Anke Brandsma
Publikováno v:
PLoS ONE, Vol 12, Iss 9, p e0183815 (2017)
BACKGROUND:Lung fibroblasts are involved in extracellular matrix homeostasis, which is mainly regulated by transforming growth factor-beta (TGF-β), and are therefore crucial in lung tissue repair and remodeling. Abnormal repair and remodeling has be
Externí odkaz:
https://doaj.org/article/a1c4e64eac584547a246520d669c54c3
Autor:
Chavan Priyanka Yashwant, Vijay Rajendran, Srinivasan Krishnamoorthy, Baskaran Nagarathinam, Ashish Rawson, Arunkumar Anandharaj, Vignesh Sivanandham
Publikováno v:
Food Science and Biotechnology. 32:863-874
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0acdac3afded01a8798eb84d3d7128e4
https://doi.org/10.1007/s10068-022-01222-9
https://doi.org/10.1007/s10068-022-01222-9
Autor:
Maya H Buch, Bernard Combe, José A Gómez-Puerta, Roberto Caporali, Jacques-Eric Gottenberg, Paul Van Hoek, Vijay Rajendran, Pieter-Jan Stiers, Katrien Van Beneden, Daniel Aletaha, Gerd Burmester, René Westhovens, Yoshiya Tanaka
Publikováno v:
Rheumatology. 62
Background/Aims Filgotinib (FIL) is a Janus kinase 1 preferential inhibitor approved for treatment of moderate-severe active RA. A numerically higher proportion of patients (pts) ≥65y vs Methods This post hoc analysis assessed safety and efficacy i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a88db40c88f5fa1a8e8e789092211e3f
https://doi.org/10.1093/rheumatology/kead104.006
https://doi.org/10.1093/rheumatology/kead104.006
Autor:
Patrick Durez, Eugen Feist, Ricardo Blanco, Vijay Rajendran, Nadia Verbruggen, Katrien Van Beneden, James Galloway
Publikováno v:
Rheumatology. 62
Background/Aims Reporting of treatment-emergent adverse events (TEAEs) in rheumatoid arthritis (RA) clinical trials can be summarized as exposure-adjusted incidence rates (EAIRs) or exposure-adjusted event rates (EAERs). Censored EAIR (EAIR), weighin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d356b63a0dcd421652889bd7ece3568
https://doi.org/10.1093/rheumatology/kead104.160
https://doi.org/10.1093/rheumatology/kead104.160
Autor:
Maya H Buch, Gerd R Burmester, Xavier Mariette, Christina Charles-Schoeman, Vijay Rajendran, Pieter-Jan Stiers, Agustin Cerani, Paul Van Hoek, Katrien Van Beneden, Yoshiya Tanaka, Hendrik Schulze-Koops, René Westhovens, Ennio Favalli
Publikováno v:
Rheumatology. 62
Background/Aims The safety profile of filgotinib (FIL), a second-generation oral Janus kinase (JAK) 1 preferential inhibitor approved in Europe, Japan, and the UK for treatment of rheumatoid arthritis (RA) has been reported. In patients (pts) with ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ce527194fe5dca05cc9f9829e6bfb6b
https://doi.org/10.1093/rheumatology/kead104.152
https://doi.org/10.1093/rheumatology/kead104.152
Autor:
Khalid Ahmed Shareef, Bernie Cooper, Mohsen Qaidi, Nabeel Ebrahim Mohd Al Jallabi, Fuad A. Hussain Alasfor, Vijay Rajendran
Publikováno v:
The Minerals, Metals & Materials Series ISBN: 9783031225314
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::11f57fafa95e5e09c4b8deb3e450b143
https://doi.org/10.1007/978-3-031-22532-1_113
https://doi.org/10.1007/978-3-031-22532-1_113
